NCT02961803View on ClinicalTrials.gov

MD1003-AMN MD1003 in Adrenomyeloneuropathy

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2017

Conditions
AdrenomyeloneuropathyAdrenoleukodystrophyAMN
Interventions
DRUG

MD1003 100 mg capsule

DRUG

Placebo

Trial Locations (4)

75651

Groupe Hospitalier Pitié-Salpêtrière, Paris

94275 Cedex

Hôpital Bicêtre, Le Kremlin-Bicêtre

04779

MS-Ambulanz Fachkrankenhaus Hubertusburg, Wermsdorf

08908

Hospital Duran i Reynals / Bellvitge, Barcelona

Sponsors
All Listed Sponsors
lead

MedDay Pharmaceuticals SA

INDUSTRY

NCT02961803 - MD1003-AMN MD1003 in Adrenomyeloneuropathy | Biotech Hunter | Biotech Hunter